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Background: Both non-alcoholic fatty liver disease (NAFLD) and Type 2 diabetes increase the risk of developing
cardiovascular disease. The metabolic processes underlying NAFLD and Type 2 diabetes are part of an integrated
mechanism but little is known about how these conditions may differentially affect the heart. We compared the
impact of NAFLD and Type 2 diabetes on cardiac structure, function and metabolism.
Methods: 19 adults with Type 2 diabetes (62 ± 8 years), 19 adults with NAFLD (54 ± 15 years) and 19 healthy
controls (56 ± 14 years) underwent assessment of cardiac structure, function and metabolism using high resolution
magnetic resonance imaging, tagging and spectroscopy at 3.0 T.
Results: Adults with NAFLD and Type 2 diabetes demonstrate concentric remodelling with an elevated eccentricity
ratio compared to controls (1.05 ± 0.3 vs. 1.12 ± 0.2 vs. 0.89 ± 0.2 g/ml; p < 0.05). Despite this, only the Type 2
diabetes group demonstrate significant systolic and diastolic dysfunction evidenced by a reduced stroke index
(31 ± 7vs. controls, 38 ± 10, p < 0.05 ml/m2) and reduced E/A (0.9 ± 0.4 vs. controls, 1.9 ± 1.4, p < 0.05) respectively.
The torsion to shortening ratio was higher in Type 2 diabetes compared to NAFLD (0.58 ± 0.16 vs. 0.44 ± 0.13;
p < 0.05). Significant associations were observed between fasting blood glucose/HbA1c and diastolic parameters as
well as the torsion to shortening ratio (all p < 0.05). Phosphocreatine/adenosine triphosphate ratio was not altered
in NAFLD or Type 2 diabetes compared to controls.
Conclusions: Changes in cardiac structure are evident in adults with Type 2 diabetes and NAFLD without overt
cardiac disease and without changes in cardiac energy metabolism. Only the Type 2 diabetes group display
diastolic and subendocardial dysfunction and glycemic control may be a key mediator of these cardiac changes.
Therapies should be explored to target these preclinical cardiac changes to modify cardiovascular risk associated
with Type 2 diabetes and NAFLD.
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Type 2 diabetes effects ~5% of Western populations,
with prevalence rates significantly higher in East and
South Asian communities [1]. Non-alcoholic fatty liver
disease (NAFLD) is reported to effect between 20 and
30% of Western populations [2], can be as high as 60%* Correspondence: michael.trenell@ncl.ac.uk
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unless otherwise stated.in urban East and South Asian groups [3], and is closely
related to the development of Type 2 diabetes [4].
Indeed, in excess of 90% of obese people with Type 2
diabetes have NAFLD [5]. The strong relationship bet-
ween NAFLD and Type 2 diabetes lies in the central role
of the liver lipids in glucose homeostasis [6].
Heart disease is the leading cause of morbidity and
mortality in both Type 2 diabetes and NAFLD [7,8]. In-
dividuals with diabetes demonstrate a 74% greater risk
of hospitalisation due to heart failure [9]. NAFLD,
characterized by elevated serum γ-glutamyltransferase. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Cassidy et al. Cardiovascular Diabetology  (2015) 14:23 Page 2 of 11(GGT), is independently associated with heart failure
[10]. The increased incidence of cardiovascular mor-
bidity and mortality associated with Type 2 diabetes and
NAFLD, has been linked to preclinical changes in car-
diac structure, function and metabolism.
The most commonly reported change in asymptomatic
individuals with Type 2 diabetes is diastolic dysfunction
[11-14], alongside decreased end-diastolic blood volume
[11], and changes in cardiac strain patterns [15]. These
cardiac changes have been associated with myocardial
steatosis [16], michondondrial dysfunction [17], changes
in calcium regulation, and myocardial fibrosis [18].
NAFLD is also characterized by a similar pattern of dia-
stolic dysfunction [19,20], altered left ventricular geo-
metry [19], reduced myocardial perfusion reserve [21]
and changes in cardiac strain [22]. Although a growing
body of epidemiological and clinical evidence links the
disease processes of Type 2 diabetes and NAFLD, little
is known about how these conditions may differentially
affect the heart.
Using magnetic resonance imaging (MRI) we have pre-
viously shown pre-clinical changes in cardiac structure
and function in NAFLD [22]. To extent this work and in
light of the importance of understanding early cardiac
changes and reducing cardiovascular risk in people with
metabolic disease, the present study was designed to
compare the impact of Type 2 diabetes and NAFLD
upon cardiac structure, function and metabolism and to
identify potential metabolic mediators.Methods
Participants
In a case control study, 19 participants with NAFLD and
19 participants with Type 2 diabetes were recruited into
the study through Newcastle upon Tyne Hospitals NHS
Foundation Trust. NAFLD was defined as >5% intrahe-
patic lipid on 1H-magnetic resonance spectroscopy of
the liver (see below for detailed methods) with no evi-
dence of advanced fibrosis (mean alanine aminotransfer-
ase / aspartate aminotransferase (AST/ALT) 0.82 ± 0.08).
Patients with >5% intrahepatic lipid were excluded from
the NAFLD group if they had a previous diagnosis of
Type 2 diabetes, were on any glucose lowering medica-
tion, had an HbA1c ≥48 mmol/mol or had any second-
ary causes of hepatic steatosis as listed in [23]. Type 2
diabetes participants had been previously diagnosed by
their GP (diagnosis length 5 ± 4 years) and were diet or
metformin controlled only. Both groups had no previous
history of cardiac disease. 19 controls, matched for gen-
der, were recruited from advertisements in local newspa-
pers and were without hypertension, metabolic, liver or
cardiac disease. Participant characteristics are presented
in Table 1.Experimental protocol
All participants were screened with resting blood pres-
sure measurements (Suntech Tango+, Suntech Medical
Ltd, Oxford), maximal cardiopulmonary stress testing
with a 12-lead ECG (Custo med GmbH, Ottobrunn,
Germany) and height and weight measurements using a
stadiometer and electronic scale respectively (SECA,
Birmingham, UK). Following screening, participants un-
derwent fasting blood measurements. All study partici-
pants then underwent a magnetic resonance protocol
including cine imaging, cardiac tagging, and phosphorus
cardiac spectroscopy, hepatic spectroscopy and visceral
fat analysis performed during a single session. Written
informed consent was obtained from each participant.
The study protocol was approved by Newcastle and
North Tyneside 1 Research Ethics Committee.
Fasting blood measures
Fasting blood samples were analyzed for whole blood glu-
cose (YSI 2300 Stat Plus-D, Yellow Springs Instruments,
Yellow Springs, OH). ALT, total cholesterol, triacylglycer-
ols and HbA1c were analysed in a clinical pathology ac-
credited laboratory (Newcastle Upon Tyne Hospital NHS
Foundation Trust, Department of Clinical Biochemistry)
in both patient groups.
Cardiac cine imaging
A 3 T Philips Intera Achieva scanner (Best, NL) was
used for cardiac examinations.
A dedicated six-channel cardiac coil (Philips) was used
with the participants in a supine position and ECG gating.
Short-axis balanced steady-state free precession images
were acquired covering the left ventricle (FOV = 350 mm,
TR/TE = 3.7/1.9 ms, acceleration factor 17, flip angle 40°,
slice thickness 8 mm, 0 mm gap, 14 slices, 25 phases, reso-
lution 1.37 mm). Analysis was performed using view
forum workstation (Philips) on short axis slices at
end-diastole and end-systole (Figure 1a). Details of our
algorithms for calculating left ventricular mass, wall thick-
nesses, blood pool volumes and measures of systolic and
diastolic function have been previously published [24].
The eccentricity ratio, a measure of concentric remodel-
ling, was calculated by dividing left ventricular mass by
end-diastolic blood volume.
Preload, afterload, contractility, and ventricular-arterial
coupling were calculated from this data in combination
with blood pressure measurements. Preload was deter-
mined by the end-diastolic volume, afterload by arterial
elastance [(Ea) = end-systolic pressure (systolic blood
pressure x 0.9)/stroke volume (normalized to body sur-
face area)], contractility by end-systolic elastance [(Ees) =
end-systolic pressure/end-systolic volume (normalized
to body surface area)], and ventricular-arterial coupling
by the ratio of Ees/Ea.
Table 1 Demographic and metabolic characteristics of study population by group
Variable Controls NAFLD Type 2 diabetes P value
(n = 19) (n = 19) (n = 19)
Age (yr) 56 ± 14 54 ± 15 62 ± 8 0.127
Gender (men:women) 11:8 11:8 11:8 -
Height (cm) 169 ± 11 169 ± 9 168 ± 9 0.877
Weight (kg) 78 ± 11 83 ± 14 91 ± 14* 0.013
BMI (kg/m2) 28 ± 4 29 ± 3* 33 ± 5* 0.012
Body surface area (m2) 1.9 ± 0.2 1.9 ± 0.2 2.0 ± 0.2* 0.018
Visceral adipose tissue (cm2) - 154 ± 47 191 ± 75 0.120
Systolic blood pressure (mmHg) 131 ± 11 146 ± 16* 145 ± 17* 0.003
Diastolic blood pressure (mmHg) 82 ± 8 90 ± 12 89 ± 12 0.096
VO2peak (ml min
−1 kg−1) - 24 ± 6 19 ± 5† 0.007
Fasting Glucose (mmol/L) 5.2 ± 0.5 5.0 ± 0.6 7.2 ± 1.4*† 0.000
HbA1c (mmol/mol) - 38 ± 5 58 ± 10† 0.000
(%) (5.6 ± 0.4) (7.4 ± 0.9)
Intrahepatic lipid (%) 2.5 ± 0.9 9.4 ± 4.3* 7.9 ± 6.7* 0.000
ALT (U.L) 23 ± 12 51 ± 39* 30 ± 11 0.013
Total cholesterol (mmol/L) 5.3 ± 0.7 5.1 ± 1.2 4.7 ± 1.4 0.342
Triglycerides (mmol/L) 1.7 ± 0.9 1.5 ± 0.8 1.3 ± 1.1 0.328
Medications -
Statins 0 4 10
Blood pressure 0 1 8
Metformin 0 0 12
Data are means ± SD.
*Significant difference disease vs. control (p < 0.05).
†Significant difference Type 2 diabetes vs. NAFLD (p < 0.05).
VO2peak, peak oxygen consumption; ALT, alanine aminotransferase.
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Cardiac tagging works by applying radiofrequency pulses
to cancel magnetic resonance signal from the myocar-
dium in diastole in a rectangular grid pattern and track-
ing the deformation of these tags through the rest of the
cardiac cycle (Figure 1a + b). A turbo field echo sequence
with acceleration factor 9 was used to collect short axis
slices (TR/TE/FA/NEX =4.9/3.1/100/1, SENSE factor 2,
FOV 350x350mm, voxel size 1.37 mm, tag spacing
7 mm). The detailed protocol and analysis procedure to
derive cardiac circumferential strain, torsion and the
torsion to shortening ratio have been previously pub-
lished [22].
Cardiac spectroscopy
Cardiac high-energy phosphate metabolism was assessed
using 31P-MRS (Figure 1c). With participants lying in a
prone position with their heart at magnet isocentre, data
was collected using a 10 cm diameter 31P surface coil
(Pulseteq, UK) for transmission/reception of signal. A
slice selective, cardiac-gated cardiac gated 1-dimensional
chemical shift imaging (1D-CSI) sequence was used toeliminate contamination from the liver, with spatial pre-
saturation of lateral skeletal muscle to avoid spectral con-
tamination. Sixteen coronal phase-encoding steps were
used, yielding spectra from 10-mm slices (TR = heart rate,
192 average, approx. 20-min acquisition time). Spectral lo-
cations were overlaid onto an anatomical image and the
first spectrum arising entirely beyond the chest wall was
selected. Details of our processing and correction of the
spectra for blood contamination, saturation and excitation
flip angle have been published previously [22].
Liver and visceral fat measurement
Intrahepatic lipid was measured by localized T2-corrected
1H-magnetic resonance spectroscopy at multiple echo
times using the point-resolved spectroscopy (PRESS)
sequence: TR/TEs = 3000 ms/36,50,75,100,125,150 ms,
voxel size 3x3x3cm, placed in the posterior right lobe to
avoid major vessels. Visceral fat content was performed by
acquiring images at the L4/L5 junction using a three-
point Dixon sequence (TR/TE/number of averages/flip
angle 50 ms/3.45, 4.60, 5.75 ms/1/5°, matrix 160×109, me-
dian field of view (FOV) 440 mm, range 400–480 mm to
Figure 1 Cardiac MRI techniques. These include (a) Cardiac cine
imaging (top) and cardiac tagging (bottom) at diastole (left) and
systole (right), showing how a rectangular grid of nulled signal applied
at diastole remains with the tissue through the cardiac cycle, allowing
calculation of strain and torsion. (b) Tagging in two parallel sections
allows the calculation of the torsion (the longitudinal-circumferential
shear angle ϒ) between two short-axis planes a distance d apart with
radius r where one short-axis plane rotates through ΔΦ relative to the
other. ϒ = tan−1[(2r sin(ΔΦ/2))/d]. (c) Phosphorus spectroscopy from a
control subject (PCr/ATP = 1.95). Spectrum presented before correction
for saturation due to blood content, flip angle at the cardiac tissue and
heart rate.
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visceral fat analysis have been previously published [25].
Statistical analysis
Data are presented as means ± SD unless otherwise stated.
All statistical tests were two-sided and performed using
SPSS version 19 (IBM, NY, US). Continuous data were
tested for normality using the Sharipo-Wilk test. Between
group differences were evaluated using a one-way
ANOVA with Bonferroni correction methods for multiple
comparisons and a non-parametric alternative (Kruskal
Wallis) for non-normally distributed data. Spearmans rank
correlation was used to observe any relationship between
metabolic parameters and cardiac parameters. Any signifi-
cant relationships were then entered into a multiple linear
regression model, adjusting for age, systolic blood pressure
and anthropometry (body mass index (BMI), body surface
area, weight, systolic blood pressure). The goal of these
analyses was to determine which factors were responsible
for the differences in cardiac structure and function be-
tween groups. P values <0.05 were considered statistically
significant.
Results
Table 1 summarises the demographic data of the three
groups. Body weight, BMI and systolic blood pressure were
significantly higher in Type 2 diabetes and NAFLD com-
pared with controls (p < 0.05). Both NAFLD and Type 2
diabetes demonstrated increased liver fat (9.4 ± 4.3 vs.
7.9 ± 6.7 vs. 2.5 ± 0.9%; p < 0.05) while fasting glucose was
higher in Type 2 diabetes only (7.2 ± 1.4 mmol/L; p < 0.05).
Peak oxygen consumption (VO2peak) was significantly
lower in the Type 2 diabetes group compared to NAFLD
(p < 0.01). There was no significant difference in visceral
adipose tissue (p = 0.120), blood cholesterol (p = 0.342) or
triglycerides between patients and controls (p = 0.328, Table 1),
however it should be noted that both Type 2 diabetes and
NAFLD patients were taking lipid lowering medication.
Cardiac structure and systolic function
Left ventricular mass was similar in all groups (p = 0.581).
The NAFLD group demonstrated thicker walls at end-
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centric remodelling was observed in both NAFLD and
Type 2 diabetes, as shown with an increased eccentricity
ratio (1.12 ± 0.2 vs. 1.05 ± 0.3 vs. 0.89 ± 0.2 g/ml; p < 0.05)
and reduced end-diastolic volume indexed when com-
pared with healthy controls (p < 0.05) (Table 2, Figure 2a).
An increased eccentricity ratio was associated with dia-
stolic dysfunction in NAFLD (E/A: r = −0.4, p = 0.05) and




Left ventricular mass (g) 102 ± 26
Left ventricular mass indexed (g/m2) 55 ± 12
Wall thickness diastole (mm) 7 ± 1
Wall thickness systole (mm) 12 ± 2
Eccentricity ratio (g/ml) 0.89 ± 0.2
End-diastolic volume indexed (ml/m2) 64 ± 18
End-systolic volume indexed (ml/m2) 27 ± 9
Systolic function
Heart rate (bpm) 59 ± 9
Stroke volume (ml) 70 ± 19
Stroke index (ml/m2) 38 ± 10
Cardiac output (L/min) 4.0 ± 0.8
Ejection fraction (%) 59 ± 5
Longitudinal shortening (%) 16.6 ± 2.8
Arterial elastance 3.32 ± 0.85
Ventricular elastance 5.04 ± 2.05
Ventricular-arterial coupling 1.50 ± 0.35
Diastolic function
Early filling percentage (%) 69 ± 11
E/A 1.9 ± 1.4
Early diastolic filling rate (ml/s) 312 ± 121
Late diastolic filling rate (ml/s) 203 ± 73
Strain and torsion
Peak endocardial circumferential strain (%) 22 ± 5
Peak whole wall circumferential strain (%) 17 ± 3
Peak torsion (°) 6.6 ± 1.8
Torsion recoil rate (%/ms) 0.25 ± 0.12
Torsion to shortening ratio 0.51 ± 0.15
Metabolism
PCr/ATP ratio 1.9 ± 0.3
Data are means ± SD.
*Significant difference disease vs. control (p < 0.05).
†Significant difference Type 2 diabetes vs. NAFLD (p < 0.05).
PCr/ATP, phosphocreatine/Adenosine triphosphate.rate: r = −0.59, p = 0.009; Early filling %; r = −0.64,
p = 0.01) but not in the control group.
Systolic function was impaired in the Type 2 diabetes
group, evidenced by a lower stroke index (31 ± 7 vs.
38 ± 10 ml/m2; p < 0.05) and reduced longitudinal shor-
tening (13.7 ± 4 vs. 16.6 ± 2.8%; p < 0.05) when compared
to controls (Figure 2b). There were no differences in
heart rate, stroke volume, cardiac output and ejection
fraction between groups and no significant correlationsc structure, function and metabolism
NAFLD Type 2 diabetes P value
(n = 19) (n = 19)
114 ± 31 108 ± 28 0.581
59 ± 11 53 ± 12 0.273
8 ± 1* 6 ± 2*† 0.000
14 ± 3* 12 ± 3 0.016
1.12 ± 0.2* 1.05 ± 0.3* 0.004
54 ± 14 52 ± 14 0.039
21 ± 9 21 ± 10 0.63
61 ± 9 65 ± 9 0.178
64 ± 12 64 ± 17 0.437
33 ± 5 31 ± 7* 0.034
3.8 ± 0.6 4.0 ± 0.9 0.754
63 ± 8 61 ± 10 0.332
14.2 ± 2.7 13.7 ± 4* 0.017
4.07 ± 0.78* 4.38 ± 1.05* 0.004
7.62 ± 3.22* 7.72 ± 4.08* 0.011
1.82 ± 0.60 1.75 ± 0.72 0.263
65 ± 11 57 ± 9* 0.003
1.6 ± 1.3 0.9 ± 0.4* 0.015
265 ± 95 244 ± 76 0.105
212 ± 70* 288 ± 99* 0.009
28 ± 4* 24 ± 5† 0.001
19 ± 2 16 ± 4† 0.012
6.9 ± 2.2 8.0 ± 2.5 0.127
0.17 ± 0.12 0.27 ± 0.1† 0.017
0.44 ± 0.13 0.58 ± 0.16† 0.019
1.8 ± 0.3 1.8 ± 0.3 0.543
Figure 2 Measures of cardiac structure and function. (a) eccentricity ratio, (b) longitudinal shortening (c) E/A and (d) torsion to shortening
ratio, in control, NAFLD and Type 2 diabetes adults. Data are means ± SE.*Significant difference disease vs. control (p < 0.05). †Significant
difference Type 2 diabetes vs. NAFLD (p < 0.05).
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function with fasting glucose or HbA1c. Arterial elas-
tance (afterload) and ventricular elastance (ventricular
stiffness) were both increased in NAFLD and Type 2
diabetes compared to controls (p < 0.05) but the ratio
between the two (ventricular-arterial coupling) was not
different between groups (Table 2).
Diastolic function
The early to late filling ratio (E/A) was significantly
lower in Type 2 diabetes compared to controls (0.9 ± 0.4
vs 1.9 ± 1.4; p < 0.05) (Figure 2c) along with a decrease in
early filling percentage (p < 0.05).The NAFLD group
showed no significant change in these parameters com-
pared to controls. Both the NAFLD and Type 2 diabetes
groups displayed significant increases in late diastolic
filling rate compared to controls (212 ± 70 vs. 288 ± 99
vs. 203 ± 73 ml/s; p < 0.05). Across the three groups,
there was a moderate negative correlation between
fasting glucose and early filling percentage (r = −0.32,
p = 0.021) (Figure 3a). In addition, increased HbA1c was
associated with impaired E/A (r = −0.52, p = 0.003) and
reduced early filling rate (r =−.48, p = 0.006) (Figure 3c + d).
When controlling for the baseline differences in age, sys-
tolic blood pressure and anthropometry across groups,
glucose (β = −0.26, p < 0.05) remained a significant pre-
dictor of early filling percentage. Age was a significantpredictor of early filling percentage (β = −0.5, p < 0.01),
E/A (β = −0.66, p < 0.01) and early filling rate (β = −0.48,
p < 0.01).Cardiac torsion and strain
Cardiac torsion and strain differed across groups, with
higher endocardial circumferential strain in the NAFLD
group and elevated torsion in the Type 2 diabetes group,
as shown by the significantly higher torsion to shor-
tening ratio in Type 2 diabetes compared to NAFLD
(0.58 ± 0.16 vs. 0.44 ± 0.13, p < 0.05, Figure 2d). Peak
torsion was 24% greater in the Type 2 diabetes group
compared to controls. Fasting glucose was moderately
correlated with the torsion to shortening ratio (r = .42,
p = 0.003) (Figure 3b). When controlling for baseline dif-
ferences in age, systolic blood pressure and anthro-
pometry, the association between fasting glucose and the
torsion to shortening ratio was approaching significance
(β = 0.25, p = 0.072).Similarly, age was approaching sig-
nificance in predicting the torsion to shortening ratio
(β = 0.29, p = 0.057).Cardiac metabolism
There was no difference in phosphocreatine/adenosine tri-
phosphate (PCr/ATP) amongst NAFLD and Type 2 dia-
betes adults compared to controls (1.8 ± 0.3 vs. 1.8 ± 0.3
Figure 3 Associations between glycemic control and measures of cardiac function. Triangle = Control, Square = NAFLD, Circle = Type 2
diabetes. Relationships between (a) fasting glucose and early filling percentage, (b) fasting glucose and torsion to shortening ratio, (c) HbA1c and
E/A and (d) HbA1c and early filling rate, are presented in the figure. HbA1c, haemoglobin A1c.
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measures of cardiac structure or function.
Discussion
This is the first study to compare the effect of Type 2
diabetes and NAFLD on cardiac structure, function and
metabolism using the most sensitive cardiac magnetic
resonance techniques. The major findings suggest that
despite similar levels of concentric remodelling, individ-
uals with Type 2 diabetes demonstrate significantly
greater diastolic and subendocardial dysfunction in com-
parison with NAFLD and healthy adults. There were sig-
nificant relationships between glycaemic control and
measures of cardiac function, suggesting that hypergly-
cemia itself is an important factor contributing to these
sub-clinical cardiac changes.
The results indicate concentric remodelling in both
NAFLD and Type 2 diabetes independent of changes in
left ventricular wall mass. Using similar magnetic reson-
ance techniques, Diamant et al. [12] also failed to dem-
onstrate an increase in left ventricular wall mass in
adults with Type 2 diabetes which is in contrast to stud-
ies using echocardiography [26]. Echocardiography has
however been found to overestimate cardiac size [27]. In
both NAFLD and Type 2 diabetes, an increased eccentri-
city ratio was associated with diastolic dysfunction. Wespeculate that the reduced left ventricular cavity may im-
pair diastolic filling. The NAFLD group display more
prominent structural changes than the Type 2 diabetes
group, with thicker walls at diastole and systole. This en-
ables the left ventricle to generate increased force and
pressure thereby preserving systolic function [28].
The data show left ventricular diastolic and systolic
dysfunction in Type 2 diabetes but not NAFLD, despite
equivalent degrees of blood pressure and concentric
remodelling. Early diastolic filling due to ventricular
relaxation accounts for roughly 80% of ventricular end-
diastolic volume in a young healthy heart and declines
with age [29]. Impaired early filling observed in the
present study indicates greater myocardial stiffness. Dia-
stolic dysfunction is an independent predictor of mor-
tality [30] which warrants the need for therapies to
target these preclinical cardiac changes. A recent longi-
tudinal study demonstrated no decline in diastolic dys-
function after 6 years of follow up in adults with Type 2
diabetes, when cardiovascular risk factors (such as blood
pressure, BMI and blood glucose) were managed [13].
Interventions targeting these risk factors therefore need
to be a priority in the treatment of diastolic dysfunction.
The present study uses MRI which is in contrast to the
aforementioned study and many other reports in the lit-
erature. MRI provides a robust non-invasive assessment
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for measures of cardiac structure, enabling the measure-
ment of cardiac changes in a unique non-invasive way.
Analysis of cardiac deformation by 3D magnetic reson-
ance tagging demonstrated a raised torsion to shortening
ratio in Type 2 diabetes with peak torsion 24% greater in
this group. A decrease in circumferential and longitu-
dinal strain accompanied with a rise in torsion has been
previously reported in Type 2 diabetes [15]. The torsion
to shortening ratio is a marker of the dominance of sub-
epicardial fibres exerting their effects over the suben-
docardium [31]. Torsion is a normal feature of cardiac
contraction and results in a counter clockwise twisting
motion when viewed from the apex to base. Subepicar-
dial fibres act over a larger radius, therefore, during con-
traction they are dominant over subendocardial fibres
which partially counteract this twisting motion [31].
The relative dysfunction of the subendocardium in Type
2 diabetes, manifested as an increase in torsion could be
attributed to subendocardial fibrosis [31]. Subendocar-
dial dysfunction reduces longitudinal shortening as
demonstrated in this study. In contrast to Type 2 dia-
betes, NAFLD participants demonstrate increased strain
and maintained torsion when compared to controls.
The large difference in radii between epicardial and
endocaridal fibres (due to both increased wall thickness
and reduced end-diastolic blood volume indexed) in
NAFLD, means endocardial strain has to increase for
torsion to be maintained.
Across the three groups, age and fasting blood glucose
were predictors of the changes in cardiac function. It has
been previously demonstrated that age is associated with
diastolic dysfunction and an increase in the torsion to
shortening ratio [29,31,32], and our results confirm these
findings. Despite this, fasting blood glucose independent
of age, influenced cardiac function, suggesting that meta-
bolic disease exaggerates the ageing phenotype. The rela-
tive contribution of liver fat and other metabolic
parameters (BMI, Systolic Blood Pressure, Total Choles-
terol, Triglyceride) with cardiac complications is an im-
portant question. In the linear regression model, there
were no consistent predictors of cardiac dysfunction
other than blood glucose. However, to fully explore this
question larger studies are required. The relationship
with blood glucose is of interest. We speculate that
NAFLD participants who have high liver fat with stable
blood glucose demonstrate higher endocardial strain and
structural compensation to maintain cardiac function.
The progression to Type 2 diabetes which is charac-
terised by high blood glucose may lead to endocardial
damage, resulting in impaired function. This is reflected
in the significant relationship between blood glucose and
measures of cardiac function across the three groups.
Preventing a rise in blood glucose should therefore be apriority in the clinical management of NAFLD. The
postulated interactions between cardiac parameters
in NAFLD and Type 2 diabetes are summarised in
Figure 4.
It has been previously demonstrated that poor gly-
cemic control is associated with an increased risk of
heart failure in adults with Type 2 diabetes [33]. The
present study builds on this by demonstrating an associ-
ation between glycemic control and changes in myocar-
dial function. The relationship between cardiac torsion
and glycemic control has not been previously shown and
only a few studies have demonstrated a relationship bet-
ween glucose control and diastolic function [11,16].
Direct primary effects on the myocardium or secondary
effects on peripheral resistance (afterload) are two path-
ways in which blood glucose could interfere with dia-
stolic function. This is because diastolic distensibility
(raised diastolic pressure at any level of diastolic volume)
can arise from altered myocardial elastic properties
(fibrosis) or prolongation of ventricular relaxation [34].
Raised afterload slows ventricular relaxation which can
alter the pressure gradient required during early diastolic
filling and elevations in afterload have been shown to
induce left ventricular diastolic dysfunction [35]. In this
study, arterial elastance (afterload) was increased in
Type 2 diabetes and NAFLD but was not associated with
glucose control. This is suggestive of a direct impact of
glucose on the myocardium rather than peripheral
resistance.
Despite changes in structure and function, cardiac
high energy phosphate metabolism was similar between
the three groups. A PCr/ATP ratio reduction of 35%
has previously been demonstrated in participants with
Type 2 diabetes [36] and a 13% reduction in NAFLD,
compared to healthy controls [37]. The reduction in
PCr/ATP ratio has also been correlated with diastolic
dysfunction in people with Type 2 diabetes leading the
authors to postulate increased concentration of NEFA in
metabolic disease causes a switch from glucose to lipid
cardiac metabolism, reducing efficiency of ATP pro-
duction and causing cardiac functional changes [12].
However, the characteristics of the Type 2 diabetes par-
ticipants in the aforementioned study were different from
those in the present study. Specifically, they were not
taking lipid-lowering medication and therefore had higher
levels of triglyceride and total cholesterol values. Indeed,
when participants were following current NICE guidelines
[38] and using lipid-lowering medications, the PCr/ATP
ratio between Type 2 diabetes and controls were compar-
able [11]. In the present study, triglyceride and cholesterol
levels were similar in Type 2 diabetes, NAFLD and con-
trols which could explain the lack of secondary diffe-
rence in cardiac metabolism. These data also suggest
that changes in high energy phosphate metabolism may
Figure 4 Postulated interactions between cardiac parameters across controls, NAFLD and Type 2 diabetes.
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than an underlying metabolic defect in the myocardium.
Limitations of the study should be considered. The cross
sectional nature does not allow insight into causality of the
abnormalities identified. Hypertension is a common co-
morbidity in metabolic disease which complicates the dis-
tinction of the separate impact of glucose control and high
blood pressure on cardiac function. However, blood glu-
cose had a significant relationship with measures of cardiac
function independent of blood pressure. The present
manuscript focused on functional and metabolic changes
but does not measure perfusion or steatosis, two mediators
of metabolism and function, due to the duration of MRI
scans and tolerability by patients. Myocardial triglyceride
accumulation is an early sign of heart disease in Type 2
diabetes and is associated with changes in cardiac function,
in particular diastolic dysfunction [16,39,40]. The present
data reinforces the need for further exploration of the
interrelationship between, glycemic control, cardiac func-
tion/metabolism, perfusion and steatosis. In addition, we
were unable to assess stress MRI meaning cardiac abnor-
malities have only been identified at rest.
Conclusions
In summary, changes in cardiac structure are evident in
adults with Type 2 diabetes and NAFLD without overtcardiac disease and without changes in cardiac energy
metabolism. The growing prevalence of metabolic disor-
ders puts large numbers at risk of these underlying car-
diac changes. Only the Type 2 diabetes group display
diastolic and subendocardial dysfunction and glycemic
control may be a key mediator of these cardiac changes.
Managing blood glucose should therefore be a priority
for clinical care teams to prevent cardiac complications
in adults with Type 2 diabetes and NAFLD.
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